This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giagounidis, A. A.N. Articles by Aul, C. Search for Related Content PubMed PubMed Citation Articles by Giagounidis, A. A.N. Articles by Aul, C. Related Collections Cellular Pathobiology Cellular Pathobiology: Cancer Genes and Genomics

Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies

Authors' Affiliations: ¹ St. Johannes Hospital, Medizinische Klinik II, Duisburg, Germany and ² Heinrich-Heine-Universität Düsseldorf, Klinik für Hämatologie, Onkologie und klinische Immunologie, Düsseldorf, Germany

Requests for reprints: Aristoteles A.N. Giagounidis, St. Johannes Hospital, Medizinische Klinik II, An der Abtei 7-11, 47166 Duisburg, Germany. Phone: 49-203-546-2480; Fax: 49-203-546-2249; E-mail: gia{at}krebs-duisburg.de.

The presence of del(5q), either as the sole karyotypic abnormality or as part of a more complex karyotype, has distinct clinical implications for myelodysplastic syndromes (MDS) and acute myeloid leukemia. The 5q– syndrome, a subtype of low-risk MDS, is characterized by an isolated 5q deletion and <5% blasts in the bone marrow and can serve as a useful model for studying the role of 5q deletions in the pathogenesis and prognosis of myeloid malignancies. Recent clinical results with lenalidomide, an oral immunomodulatory drug, have shown durable erythroid responses, including transfusion independence and complete cytogenetic remissions in patients with del(5q) MDS with or without additional chromosomal abnormalities. These results indicate that lenalidomide can overcome the pathogenic effect of 5q deletion in MDS and restore bone marrow balance. The data provide important new insights into the pathobiology of 5q chromosomal deletions in myeloid malignancies.

This article has been cited by other articles:

				L. Wang, C. Fidler, N. Nadig, A. Giagounidis, M. G. Della Porta, L. Malcovati, S. Killick, N. Gattermann, C. Aul, J. Boultwood, et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays Haematologica, July 1, 2008; 93(7): 994 - 1000. [Abstract] [Full Text] [PDF]

				L. P. Gondek, R. Tiu, C. L. O'Keefe, M. A. Sekeres, K. S. Theil, and J. P. Maciejewski Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML Blood, February 1, 2008; 111(3): 1534 - 1542. [Abstract] [Full Text] [PDF]

				A. Pellagatti, M. Jadersten, A.-M. Forsblom, H. Cattan, B. Christensson, E. K. Emanuelsson, M. Merup, L. Nilsson, J. Samuelsson, B. Sander, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients PNAS, July 3, 2007; 104(27): 11406 - 11411. [Abstract] [Full Text] [PDF]

				D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. Moutouh-de Parseval, K. Jensen-Pergakes, P. H. Schafer, R. Chen, E. Glezer, G. D. Ferguson, et al. Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells Cancer Res., January 15, 2007; 67(2): 746 - 755. [Abstract] [Full Text] [PDF]

				P. Fenaux and C. Kelaidi Treatment of the 5q- Syndrome Hematology, January 1, 2006; 2006(1): 192 - 198. [Abstract] [Full Text] [PDF]